Nanostics
Precision Health. Accurate Results. Focused on development and commercialization of novel, non-invasive diagnostic tests.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
* | N/A | Grant | |
| Total Funding | 000k | ||
Related Content
Nanostics is a commercial stage precision health company focused on developing innovative diagnostic tools to improve healthcare decisions. The company operates in the medical device and biotechnology sectors, primarily serving healthcare providers and patients. Nanostics' flagship product, ClarityDX Prostate, leverages machine learning and blood-based biomarkers to accurately predict the risk of aggressive prostate cancer, thereby reducing the need for invasive biopsies. The business model revolves around selling diagnostic tests and related services to healthcare institutions. Revenue is generated through the sale of these tests and ongoing support services. Nanostics aims to bring clarity to healthcare decisions, enhancing patient outcomes and reducing unnecessary medical procedures.
Keywords: precision health, prostate cancer, diagnostic tools, machine learning, biomarkers, healthcare decisions, medical device, biotechnology, invasive biopsies, patient outcomes.